Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

Apogenix GmbH. (6/3/15). "Press Release: Apogenix Appoints Peter Willinger as New CFO". Heidelberg.

Organisations Organisation Apogenix GmbH
  Today Apogenix AG
  Organisation 2 Sygnis Pharma AG
  Today Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Expedeon (Group)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 genomic technology
Persons Person Willinger, Peter (Apogenix 201506– CFO before Sygnis Pharma + Lion Bioscience)
  Person 2 Höger, Thomas (Apogenix 200511– CEO + CFO before since 10/00 DZ Bank before BASF/Knoll)

Apogenix, a next generation immuno-oncology company, announced today the appointment of Peter Willinger as Chief Financial Officer. As head of the finance division, he will be responsible for the long-term financing of the company to support its continued growth.

Peter Willinger has 15 years of financial management experience in the life sciences and biotech industries. Before joining Apogenix, he was CFO of LION bioscience AG/SYGNIS Pharma AG where he oversaw the finance, investor relations, and corporate development departments. He successfully supported the company’s IPO and contributed to numerous capital increases. He was further responsible for the strategic realignment and restructuring of the corporation.

“We are excited about Peter Willinger joining the Apogenix management team,” said Thomas Hoeger, Ph.D., Chief Executive Officer of Apogenix. “He has extensive experience as chief financial officer of an international biotech company, and we are convinced that he will contribute significantly to the successful development of Apogenix.”

Peter Willinger added: “I look forward to my new role as CFO of Apogenix. Apogenix focuses on immuno-oncology, which is a very exciting field, and the company’s immunotherapy pipeline has enormous growth potential.”

About Apogenix

Apogenix is a next generation immuno-oncology company focusing on the development of innovative protein therapeutics for the treatment of cancer and other malignant diseases. With a dedicated, highly qualified team, we have built a promising pipeline of drug candidates that target TNFSF (tumor necrosis factor superfamily)-dependent signaling pathways. Apogenix’ TNFSF modulators re-establish the body’s immune response against tumors and inhibit invasive tumor cell growth.

Since its inception in fall 2005, Apogenix has raised more than 50 million euros from its investors and was awarded public grants totaling 8.5 million euros. The company is based in Heidelberg, Germany.


Thomas Hoeger, Ph.D., CEO
Apogenix GmbH
Phone: +49 (6221) 58 60 80

Media Contacts

Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1 (212) 845 4272

Raimund Gabriel
MC Services AG
Phone: +49 (89) 210 228 30

Record changed: 2017-04-02


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Apogenix GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top